Best Traditional Pharmaceuticals Companies in United States
The 558 best Traditional Pharmaceuticals companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ligand Pharmaceuticals.
Ranking the most-funded Traditional Pharmaceuticals companies in the United States, this directory tracks 558 firms against $7.5B in disclosed equity, ordered by funding size and recent momentum. The global market sits at roughly $180B today, forecast to nearly double to $359.4B by 2032 at a 7.7% CAGR, driven by rising consumer preference for natural and herbal therapies. That's a long runway, and the revenue data already shows what scale looks like here.
Eighteen validated filers report a combined revenue pool of $11.9B, with a median of $162M and 11% YoY growth. Forest Laboratories leads at $3.6B (up 17%), with Viatris Inc close behind at $3.5B. Mylan Inc. earns $167M net, roughly 8x the sector median of $20M, which tells you the profit ceiling for disciplined operators is real. Among our tracked companies, Affinia Therapeutics tops the funding table at $218M, with Procaps Group at $130M. I'd note the investor roster, including Tekla Capital Management and Athyrium Capital Management, skews heavily toward specialized healthcare allocators who know how to read a formulary. So if you're benchmarking fundraising strategy, that investor mix matters as much as the headline dollar figures.
- HTF Market Intelligence
Our analysis of 50 Traditional Pharmaceuticals companies
$3.2b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2016.
Ranked: Best Traditional Pharmaceuticals companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ligand Pharmaceuticals Manufacturer of drugs | $895M | 97 mo ago | 76 76 → 136 (+79%) | 1987 | Todd Davis Chief Executive Officer & Director | 11 signals ▼70% Announcements · Leadership · Earnings | — | — |
| 2 | EQRx Manufacturer of medicines | $700M | 65 mo ago | 363 | 2005 | — | — | — | — |
| 3 | Perrigo Manufacturer of APIs, OTC, and nutritional products | $600M | 117 mo ago | 8,900 8,900 → 6,044 (-32%) | 1887 | Patrick Taylor CEO | 21 signals Lawsuit · Earnings · Acquisition | 88 patents Patents concentrated in health & consumer products | 1 partnership · 1 award |
| 4 | TherapeuticsMD Provider of branded and generic prescription, and over-the-counter products targeted exclusively for women | $591M | 36 mo ago | 1 | 2008 | Brian Bernick Co-Founder | — | 352 patents Vaginal estrogen delivery formulations for hormone replacement therapy | — |
| 5 | GSMS Generic pharmaceutical supplier providing quality medications, unique packaging, and exceptional service | $470M | 84 mo ago | 79 | 1986 | Benjamin Hall CEO & President | — | — | — |
| 6 | Lykos Developer of therapeutics to treat mental health conditions | $315M | 29 mo ago | — | 2014 | Amy Emerson CEO | — | — | — |
| 7 | Vertice Pharma Acquire and develop branded and generic specialty pharmaceuticals | $300M | 127 mo ago | 45 | 2015 | — | — | — | — |
| 8 | Synthekine Developer of cytokine therapeutics | $290M | 41 mo ago | 104 | 2018 | Debanjan Ray Chief Executive Officer | — | 290 patents Engineered IL‑10 cytokine therapeutics and synthetic immunomodulatory fusion proteins | — |
| 9 | Amneal Manufacturer of generics formulations | $269M | 91 mo ago | 1,441 | 2002 | Chintu Patel Co-Chief Executive Officer | 17 signals Earnings · M&A | — | — |
| 10 | M8 Pharmaceuticals Pharmaceutical company develop and commercialize leading original medicines | $264M | 88 mo ago | 300 | 2007 | — | — | 437 patents Small-molecule modulators of CXCR4/CXCR2, BTK, IL‑6 and complement for immunotherapy | — |
| 11 | Affinia Therapeutics Develops Adeno-associated viruses(AAV) for gene therapy | $218M | 9 mo ago | 64 | 2019 | Rob Aboud Co-Founder and Chief Legal Officer | — | — | — |
| 12 | The Alvogen Developer and marketer of pharmaceutical products | $156M | 59 mo ago | 2,800 | 2009 | Lisa Graver Chief Executive Officer | — | 8 patents Controlled-release oral tablet formulations for pregabalin drug delivery | — |
| 13 | Sagent Pharma Provider of injectable generic pharmaceuticals | $153M | 194 mo ago | 233 | 2006 | — | — | — | 1 launch · 1 partnership · 1 award |
| 14 | Coherus Biosciences Developer of biosimilar therapeutics | $144M | 74 mo ago | 233 | 2010 | — | 3 signals ▼88% Leadership · M&A | 510 patents Therapeutic antibodies and biologic purification for oncology and ocular disease treatments | — |
| 15 | Procaps Group Pharmaceutical and nutraceutical solutions company that develops, manufactures, and distributes a range of… | $130M | 14 mo ago | — | 1999 | Ruben Minski Founder & CEO | — | 28 patents Innovative tablet feeding and bubble‑free solid dosage encapsulation for gelatin capsules | — |
| 16 | Proteon Therapeutics Developer of cell therapies and investigational drug formulations for cancer and rare diseases | $127M | 106 mo ago | 17 | 2001 | — | — | — | — |
| 17 | Slayback Pharmaceuticals Manufacturer of specialty generics drugs | $110M | 77 mo ago | 7 | 2011 | — | — | — | — |
| 18 | Exo Therapeutics Manufacturer of drugs for multiple therapeutic areas | $103M | 56 mo ago | 15 15 → 16 (+7%) | 2018 | Alan Saghatelian Co-Founder | — | — | — |
| 19 | PreCision Dermatology Developer of dermatology-based products | $74M | 152 mo ago | 175 | 2010 | — | — | 3 patents Patents concentrated in health & consumer products | — |
| 20 | Sermonix Pharma Developer of female-specific oncology therapeutics | $73M | 55 mo ago | 13 | 2014 | — | — | — | — |
| 21 | SFJ Pharmaceuticals Specialty pharmaceutical company based on partnering model | $70M | 158 mo ago | 12 | 2008 | — | — | — | — |
| 22 | Rock Creek Pharmaceuticals Provider of property and casualty insurance products for homes, condos, tenants, and businesses | $68M | 122 mo ago | 10 | 1998 | — | — | — | — |
| 23 | CORE Brand of energy drinks | $66M | 98 mo ago | 15 | 2015 | — | — | 20 patents Advanced PCB manufacturing using conductive constraining cores and thermally conductive prepregs | — |
| 24 | Genexa Manufacturer of range of nutraceutical products | $60M | 39 mo ago | 23 23 → 40 (+74%) | 2014 | David Johnson Chief Executive Officer | — | 14 patents Formulating pediatric oral syrups and solid tablets for OTC cough/ cold medicines | — |
| 25 | BMP Sunstone Manufacturer of composite stone facade and finishing elements | $54M | 206 mo ago | — | 2003 | Xiaoying Gao CEO | — | — | — |
| 26 | Vensun Pharmaceuticals Developer of generic prescription pharmaceutical products | $50M | 114 mo ago | 18 | 2011 | — | — | — | — |
| 27 | Dantari Developer of pharmaceutical products | $47M | 42 mo ago | 20 | 2018 | Richard Markus CEO | — | 20 patents Polymer‑based nanoparticle delivery systems for camptothecin and other therapeutic agents | — |
| 28 | Augmenix Provider of a hydrogel spacer for prostate cancer radiation therapy | $47M | 119 mo ago | 153 153 → 100 (-35%) | 2008 | — | — | — | — |
| 29 | Petros Manufacturer of men's health therapeutic products | $40M | 35 mo ago | 24 | 2020 | John David Shulman CEO | — | — | — |
| 30 | Nivagen Pharmaceuticals Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution | $31M | 34 mo ago | 52 | 2009 | Jay S. CEO & President | — | — | — |
| 31 | Particle Dynamics Provider of particle processing, product manufacturing, and integrated services | $31M | 9 mo ago | 56 | 1990 | — | — | 20 patents Iron‑polysaccharide complexes for nutritional/pharmaceutical iron supplementation and gel dosage forms | — |
| 32 | OurPharma Manufacturer of sterile injectables and intravenous fluids | $26M | 10 mo ago | 51 | 2016 | Peter Kohler CEO | — | — | 1 launch |
| 33 | i3 Pharmaceuticals Manufacturer of drugs | $16M | 48 mo ago | — | 2015 | Sunil Sagi Co-Founder | — | 437 patents Patents concentrated in health & consumer products | — |
| 34 | Zennova Manufacturer of drugs | $14M | 34 mo ago | — | 2014 | Dahai Guo Co-Founder & CEO | — | 3 patents Analyzing dissolution and solubility of poorly soluble compounds in complex media | — |
| 35 | R & B Supply Chain Provider of pharmaceutical goods, machinery, equipment and supplies | $14M | 33 mo ago | — | — | Robert Caucci CEO | — | 151 patents Patents concentrated in transport & manufacturing processes | — |
| 36 | Abbott Developer of medical devices, generic pharmaceuticals, and nutrition products | $13M | 55 mo ago | 39,849 | 1888 | Robert Ford CEO | — | 467 patents Monoclonal antibody therapeutics targeting amyloid‑beta and related proteins for Alzheimer’s disease | — |
| 37 | Yuva Biosciences Developer of cosmeceuticals and pharmaceuticals | $9M | 3 mo ago | 5 | 2018 | Keshav Singh Founder | — | — | 1 partnership |
| 38 | Pulvinar Neuro Developer of drugs for neuroscience research services | $7M | 15 mo ago | 5 | 2016 | — | — | — | — |
| 39 | Exela Pharma Manufacturer of sterile injectable pharmaceutical products and CDMO services 48Innovation top 20%Product top 30%Growth top 40%Funding top 43% All 8 signals ▾Innovationtop 20% Producttop 30% Growthtop 40% Fundingtop 43% Talentbottom 49% Marketbottom 37% Globalbottom 32% Techbottom 31% Innovation: 8 product lines Product: 8 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 48/100 | $7M | 8 mo ago | 205 205 → 339 (+65%) | 2005 | Phanesh Koneru Co-Founder & CEO | — | — | 2 job openings · 1 award |
| 40 | Octogen Provider of pain relief products for muscle soreness and joint pain | $4M | 23 mo ago | — | 1932 | — | — | — | — |
| 41 | Cmtx Biotech Developer of small-molecule treatments for rare and pandemic diseases | $4M | 12 mo ago | 6 | 2019 | — | — | — | — |
| 42 | Petri Bio Manufacturer of microbe based drugs | $4M | 10 mo ago | 3 | 2019 | Joseph Schinaman Co-Founder | — | — | — |
| 43 | Consegna Pharma Provider of multilingual website error pages | $3M | 33 mo ago | — | 2017 | Larry Zana Founder | — | — | — |
| 44 | OWP Pharmaceuticals Manufacturer of pharmaceutical products | $3M | 10 mo ago | 22 | 2013 | — | — | — | — |
| 45 | ABVC Manufacturer of plant based medicines and devices | $3M | 10 mo ago | 23 23 → 12 (-48%) | 1990 | Uttam Patil Chief Executive Officer | — | — | — |
| 46 | AxmedRx Manufacturer of drugs | $2M | 25 mo ago | — | 2023 | Sofia Radley-Searle Co-Founder | — | — | — |
| 47 | Chorda Pharma Manufacturer of medications to treat chronic pain | $492K | 18 mo ago | — | 2017 | Victor Iannello CEO | — | — | — |
| 48 | Balanced pHarma Manufacturer and development of anesthetic drugs | $481K | 18 mo ago | 5 | 2018 | John Keadle Founder & CEO | — | — | — |
| 49 | TheraCea Pharma Developer of diagnostic tools for faster cancer and neurological disorder detection | $295K | 14 mo ago | 6 | 2019 | Justin Jeffery Co-Founder & Chief Business Officer | — | — | — |
| 50 | TissueForm Manufacturer of dermal fillers | $275K | 21 mo ago | 3 | 2019 | Jeanne Barthold Co-Founder | — | — | 1 award |
Top 12 Traditional Pharmaceuticals companies in United States
#1
Series C · Waltham, Massachusetts · founded 2019 · 64 employees$218.3Mraised▾
Develops Adeno-associated viruses(AAV) for gene therapy
- Sep 2025Series C$40M
- Apr 2021Series B$110M
- Mar 2020Series A$60M
- Oct 2019Seed$8.3M
#2
Seed · Birmingham, Alabama · founded 2018 · 5 employees$8.6Mraised▾
Developer of cosmeceuticals and pharmaceuticals
- Mar 2026Seed$1.1M
- Feb 2024Seed$7.5M
#3
Public · Miami, Florida · founded 1999$130Mraised▾
Procaps Group is a leading integrated healthcare and pharmaceutical conglomerate that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies, serving over 50 countries across five continents. The company provides a range of products and services through its various business units, including pharmaceutical manufacturing, nutraceuticals, and hospital supplies. With a presence in multiple countries, Procaps Group has established itself as a significant player in the Latin American healthcare and pharmaceutical market.
- Apr 2025Post IPO$90M
- 2024Post IPO$40M
#4
Acquired · Saint Louis, Missouri · founded 1990 · 56 employees$30.9Mraised▾
Provider of particle processing, product manufacturing, and integrated services. It offers spray drying, microencapsulation, and complex granulation services. The company manufactures products such as direct compression products, microencapsulated vitamins and minerals, and microencapsulated APIs. It also provides finished dosage forms and packaging solutions, enabling integrated services that reduce lead times and tech transfer costs. These services are targeted at the pharmaceutical, consumer health, OTC, and nutraceutical industries.
- Sep 2025Series C$30.9M
- 2019Conventional Debt—
- Jun 2010PE—
- Jun 2010Conventional Debt—
#5
Series A · Fayetteville, Arkansas · founded 2016 · 51 employees$26.1Mraised▾
OurPharma is involved in sterile compounding of injectables and intravenous fluids. Their products include syringes, injection vials, intravenous bags, and pain control devices.
- Jul 2025Series A$250K
- Feb 2023Series A$10.4M
- Aug 2019Series A$13.4M
- Dec 2017Seed$2.2M
#6
Series B · Lenoir, North Carolina · founded 2005 · 205 employees$6.7Mraised▾
Manufacturer of sterile injectable pharmaceutical products and CDMO services. This entity develops and manufactures both proprietary and generic sterile injectables. Its operations encompass the entire pharmaceutical lifecycle, from research and development to finished drug product manufacturing and distribution. Services include contract development and manufacturing, leveraging expertise in liquid vials, IV bags, lyophilized vials, and pre-filled syringes. The company also offers a range of regulatory support services.
- Sep 2025Grant (prize money)$28.3M
- Sep 2021Series B—
- Aug 2015Series A$419.8K
- Jul 2013Conventional Debt$1M
#7
Funding Raised · Los Angeles, California · founded 2019 · 3 employees$3.5Mraised▾
Manufacturer of microbe based drugs
- Jul 2025Grant (prize money)$2.2M
- May 2022Grant (prize money)$1M
- Sep 2021Grant (prize money)$361.9K
#8
Acquired · Boca Raton, Florida · founded 2008 · 1 employees$591.1Mraised▾
Provider of branded and generic prescription, and over-the-counter products targeted exclusively for women
- Jun 2023Post IPO$1.1M
- Oct 2022Post IPO$7M
- Aug 2022Post IPO$15M
- Aug 2020Series A$7.5M
#9
Public · Fremont, California · founded 1990 · 23 employees$2.7Mraised▾
Manufacturer of plant based medicines and devices
- Aug 2025Post IPO$2.5M
- Dec 2024Post IPO$200K
#10
Funding Raised · Stony Brook, New York · founded 2019 · 6 employees$3.7Mraised▾
Developer of small-molecule treatments for rare and pandemic diseases. The company focuses on clinical-stage drug candidates, prioritizing proven safety and accelerated development. Its lead drug candidate has completed IND-enabling studies and human safety testing in other indications, expediting clinical trials and market approval. A seasoned management team with expertise in drug development, commercialization, licensing, and technology transfer guides the company's efforts. The company leverages its proprietary small-molecule technology to improve patient outcomes in the treatment of orphan diseases.
- May 2025Grant (prize money)$1.3M
- Feb 2025Grant (prize money)$1.3M
- Jul 2024Grant (prize money)$300K
- May 2023Grant (prize money)$376.8K
#11
Seed · Chicago, Illinois · founded 2013 · 22 employees$2.7Mraised▾
Manufacturer of pharmaceutical products
- Jul 2025Seed$2.4M
- Jun 2024Seed$2.7M
#12
Acquired · Durham, North Carolina · founded 2016 · 5 employees$6.9Mraised▾
Developer of drugs for neuroscience research services
- Mar 2025Grant (prize money)$3.5M
- Sep 2021Grant (prize money)$55K
- Sep 2019Grant (prize money)$3.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Traditional Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in the United States
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 9,593 United States-affiliated papers.
- Harvard University331
- University of North Carolina at Chapel Hill232
- Purdue University West Lafayette200
- Cornell University172
- Stanford University170
- Computational biology126→901
- Small molecule41→351
- Chemical space26→319
- Virtual screening24→288
- Bioinformatics14→216
- Computational biology102→599
- Docking (animal)27→275
- Drug development27→259
- Virtual screening29→235
- In silico12→211
- Computational biology75→206
- Drug development47→176
- Bioinformatics18→102
- Data science20→89
- Disease13→78
Where drug discovery is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in the United States
United States drug discovery patent filing is accelerating — 762,525 filings from 8,000 assignees (2016–2025), led by UNIV California, Genentech, Bristol Myers Squibb; annual filings 69033→70331.
- UNIV California22059
- Genentech19708
- Bristol Myers Squibb19181
- Procter & Gamble16525
- Lilly ELI15557
- Pfizer15359
- Merck Sharp & Dohme14798
- Amgen14399
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.